Loading...
NPI 1356438469 · Nashville, TN · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Franco Recchia is a retina specialist (ophthalmology) physician provider located in Nashville, Tennessee. This profile covers 17 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Franco Recchia |
| Address | 345 23rd Ave N |
| City | Nashville |
| State | TN |
| ZIP | 37203 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | October 9, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.6M |
| Medicaid | $2.6K |
FRANCO RECCHIA’s Medicare billing profile is dominated by intravitreal pharmacologic therapy and associated retina care: J2777 (faricimab) accounts for 43.4% of Medicare revenue and J0178 (aflibercept) for 36.9%, with 67028 (intravitreal injection as an isolated procedure) also in the top three. The precomputed top-3 concentration is 84.7% of total Medicare revenue, which aligns with a practice model focused on high-volume injectable retina therapeutics supported by diagnostic and procedural codes.
Medicare revenue scale is material relative to Medicaid: this provider reports $3.6M in total Medicare revenue versus $2.6K in total Medicaid revenue, indicating a Medicare-dominant payer mix. Given those reported totals, the provider operates effectively as a Medicare-focused practice with only a trivial Medicaid footprint.
The provider’s Medicare revenue is highly concentrated: the precomputed top-3 Medicare codes (J2777, J0178, 67028) collectively account for 84.7% of Medicare revenue, signaling dependence on a narrow set of high-revenue treatments. This concentration heightens sensitivity of overall revenue to utilization or price changes for these specific intravitreal agents.
Competitive standing varies by code: J2777 ranks #93 of 2039 providers nationally (95th percentile) and is described as notably above typical national volume, indicating FRANCO RECCHIA is a high-volume national outlier for faricimab administration. By contrast, J0178 ranks #565 of 3204 providers nationally (82th percentile) and is characterized as typical or unremarkable volume for aflibercept, marking a strong but not exceptional position for that agent.
Diagnostic imaging and office-based retina services are also significant support lines: 92134 (computerized retinal imaging) generated $50.8K (1.4% of Medicare revenue) and ranks #1204 of 26868 providers nationally (96th percentile; notably above typical national volume), and 92250 (fundus photography) ranks #635 of 25087 (97th percentile; notably above typical national volume). Those high national percentiles for imaging indicate a substantial diagnostic throughput that complements the injection-driven revenue stream.
Procedural and surgical activity exists but is a smaller share of revenue: 67028 appears in both payers (Medicare: 1.8K claims, $154.9K revenue, 4.4% of Medicare revenue, rank #539 of 4255, 87th percentile; Medicaid: 13 claims, $2.1K revenue, 83.3% of Medicaid revenue, rank #37 of 37). The presence of 67042 (vitrectomy) with 22 claims and $18.7K revenue shows limited surgical volume relative to injection services, consistent with a clinic model that performs some operative procedures but relies primarily on injections.
Medicaid activity is negligible in scale and concentrated: total Medicaid revenue is $2.6K and the precomputed top-3 share is 100.0%, driven by 67028 at 83.3% and 92134 at 16.7%. In-state ranks for those Medicaid codes (67028 #37 of 37, 0th percentile; 92134 #78 of 81, 1th percentile) underline that this provider has minimal Medicaid throughput relative to Tennessee peers.
Practice tenure is long-standing: the NPI was enumerated 2006-10-09 (~20 years ago), indicating prolonged market presence and clinical experience. Combined with high national percentiles on select codes (for example, J2777 and 92134), the tenure suggests an established retina specialist whose revenue mix has become concentrated around modern intravitreal biologic therapies and supporting diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 53,280 | $30 | $1.5M |
| J0178 | Injection, aflibercept, 1 mg | 1,940 | $680 | $1.3M |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,780 | $90 | $154.9K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 700 | $220 | $152.3K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 530 | $160 | $82.5K |
| J2778 | Injection, ranibizumab, 0.1 mg | 350 | $170 | $60.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,820 | $30 | $50.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 640 | $80 | $50.6K |
| J3490 | Unclassified drugs | 20 | $1,710 | $30.8K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 260 | $110 | $29.8K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 15 | 80 | 790 | $680 | $769.8K |
| J2777 | 3 | 50 | 15,060 | $30 | $592.1K |
| Q5128 | 13 | 20 | 1,190 | $210 | $394K |
| J2778 | 36 | 40 | 1,340 | $180 | $370.2K |
| Q5124 | 10 | 10 | 690 | $180 | $137.8K |
| 67028 | 21 | 80 | 1,130 | $90 | $98.5K |
| J7312 | 2 | 10 | 210 | $150 | $45.8K |
| J3490 | 60 | 60 | 70 | $400 | $41.9K |
| 67042 | 21 | 40 | 20 | $1,020 | $34.5K |
| J3590 | 9 | 10 | 50 | $300 | $21.7K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 10 | $170 | $2.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 10 | $30 | $430 |
How this provider's Medicaid billing volume and revenue compare to other Tennessee providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Tennessee median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 37 | 40 | 760 | $50 | $193K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 78 | 80 | 440 | $10 | $29.6K |
Other providers in the same ZIP code as Franco Recchia, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.